lung%20cancer
LUNG CANCER
Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.

Epidemiology

  • The leading cause of cancer death worldwide & the 2nd most common cancer in both men & women 
  • It was estimated that 80-90% of all lung cancer cases are due to tobacco or cigarette smoking
    • Approximately 50% of lung cancer cases are from active smokers & approximately 15% are from second-hand smoke exposure during childhood & adolescence

Definition

  • Lung cancer develops when cells inside the lungs (lining of the bronchi) begin to grow out of control, invade nearby tissues and metastasize

Signs and Symptoms

Primary Tumor-Related

  • Cough, dyspnea, hemoptysis, chest discomfort

Due to Intrathoracic Spread

  • May involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner’s syndrome), chest wall & pleura (chest pain, dyspnea), vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dysphagia)


Due to Metastatic Spread

  • Bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, skin nodules


Paraneoplastic Syndromes

  • Hypercalcemia (nausea or vomiting, abdominal pain, constipation, polyuria, thirst, dehydration, confusion, irritability)
  • Syndrome of inappropriate antidiuretic hormone (SIADH) production (confusion, seizures, decreased level of consciousness, coma)
  • Cushing’s syndrome (weakness, muscle wasting, decreased level of consciousness, confusion, psychosis, dependent edema, hypokalemic alkalosis, hyperglycemia)
  • Others (digital clubbing, hypertrophic osteoarthropathy, Lambert-Eaton myasthenic syndrome, peripheral neuropathy, cortical cerebellar degeneration)

Other Symptoms

  • Malaise, loss of appetite & weight loss

Risk Factor Assessment

Patient Factors
  • Patients ages 65 years old and above (average is 70 years old) are at a greater risk of lung cancer development
  • Smoking cigarettes increases the risk of developing lung cancer
    • Number of packs of cigarettes smoked per day & the years spent smoking is directly related to the development of lung cancer
  • Passive smokers have 24% increased risk of developing lung cancer
  • Occupational & environmental exposures
    • Asbestos, arsenic, beryllium, chloromethyl ether, chromium, nickel, polycyclic aromatic hydrocarbons, vinyl chloride, radon, cadmium, diesel exhaust fumes, coal smoke and soot, talc, uranium
  • Previous lung disease (eg chronic obstructive pulmonary disease with FEV1 ≤70% predicted)
  • History of any cancer or thoracic radiation
    • Risk of cancer due to radiation is proportional to the dose received & usually starts approximately 20 years after exposure
  • Family history of lung cancer
  • Beta carotene supplements in heavy smokers
  • Exposure to infectious agents: [Human immunodeficiency virus (HIV), fungal infections, tuberculosis, aspiration, infectious respiratory symptoms]
  • Survivors of lung cancer, lymphomas, cancers of the head and neck or smoking-related cancers
Radiologic Factors
  • Associated with scarring or suspicion of inflammatory changes
  • Fluorodeoxyglucose (FDG) avidity (PET scan) 
  • Size, shape and density of the pulmonary nodule 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Tristan Manalac, 25 Feb 2017
Compared with viral hepatocellular carcinomas and those of other aetiologies, cryptogenic hepatocellular carcinomas tend to manifest at later stages and are associated with worse survival, according to a study presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017).
Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.